Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-1560
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial ; volume:31 ; number:6 ; day:17 ; month:10 ; year:2021 ; pages:699-711 ; date:12.2021
Clinical autonomic research ; 31, Heft 6 (17.10.2021), 699-711, 12.2021
- Urheber
-
Kaufmann, Horacio
Vickery, Ross
Wang, Whedy
Kanodia, Jitendra
Shibao, Cyndya A.
Norcliffe-Kaufmann, Lucy
Haumann, Brett
Biaggioni, Italo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10286-021-00827-0
- URN
-
urn:nbn:de:101:1-2022020418591217145229
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kaufmann, Horacio
- Vickery, Ross
- Wang, Whedy
- Kanodia, Jitendra
- Shibao, Cyndya A.
- Norcliffe-Kaufmann, Lucy
- Haumann, Brett
- Biaggioni, Italo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Neurogenic orthostatic hypotension: grand rounds
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
Neurogenic orthostatic hypotension: the very basics
Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
Update on neurogenic orthostatic hypotension : pathophysiology, prevalence and treatment
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
Orthostatic hypotension
Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms
Neurogenic orthostatic hypotension: grand rounds
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
Neurogenic orthostatic hypotension: the very basics
Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
Update on neurogenic orthostatic hypotension : pathophysiology, prevalence and treatment
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
Orthostatic hypotension
Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms
Neurogenic orthostatic hypotension: grand rounds
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
Neurogenic orthostatic hypotension: the very basics
Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
Update on neurogenic orthostatic hypotension : pathophysiology, prevalence and treatment
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
Orthostatic hypotension